An open label study, to evaluate the pharmacokinetics, safety and toleration Of a single oral dose of Pf-00868554 in subjects with hepatic impairment to subjects with normal hepatic function.
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2014
At a glance
- Drugs Filibuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Pfizer
- 23 Nov 2008 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
- 14 Oct 2008 Actual start date changed from Feb 2008 to Mar 2008 as reported by ClinicalTrials.gov.
- 14 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.